De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Zynex Beheer

Beheer criteriumcontroles 4/4

De CEO Zynex's is Thomas Sandgaard, benoemd in Jan1996, heeft een ambtstermijn van 28.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.22M, bestaande uit 53.4% salaris en 46.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 50.53% van de aandelen van het bedrijf, ter waarde $ 130.88M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 6.8 jaar.

Belangrijke informatie

Thomas Sandgaard

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris	53.4%
Dienstverband CEO	28.8yrs
Eigendom CEO	50.5%
Management gemiddelde ambtstermijn	3.9yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

With Zynex, Inc. (NASDAQ:ZYXI) It Looks Like You'll Get What You Pay For

Jul 31

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

May 03

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Mar 03

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Sep 21

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Aug 02

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Aug 01

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Jul 25

Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Jul 12

Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance

Jul 11

Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?

Apr 13

Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Mar 23

Analyse CEO-vergoeding

Hoe is Thomas Sandgaard's beloning veranderd ten opzichte van Zynex's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$6m
Mar 31 2024	n/a	n/a	US$8m
Dec 31 2023	US$1m	US$650k	US$10m
Sep 30 2023	n/a	n/a	US$16m
Jun 30 2023	n/a	n/a	US$17m
Mar 31 2023	n/a	n/a	US$17m
Dec 31 2022	US$1m	US$575k	US$17m
Sep 30 2022	n/a	n/a	US$18m
Jun 30 2022	n/a	n/a	US$20m
Mar 31 2022	n/a	n/a	US$19m
Dec 31 2021	US$988k	US$496k	US$17m
Sep 30 2021	n/a	n/a	US$10m
Jun 30 2021	n/a	n/a	US$5m
Mar 31 2021	n/a	n/a	US$5m
Dec 31 2020	US$1m	US$480k	US$9m
Sep 30 2020	n/a	n/a	US$10m
Jun 30 2020	n/a	n/a	US$11m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	US$527k	US$480k	US$9m
Sep 30 2019	n/a	n/a	US$9m
Jun 30 2019	n/a	n/a	US$10m
Mar 31 2019	n/a	n/a	US$10m
Dec 31 2018	US$1m	US$480k	US$10m
Sep 30 2018	n/a	n/a	US$10m
Jun 30 2018	n/a	n/a	US$10m
Mar 31 2018	n/a	n/a	US$9m
Dec 31 2017	US$808k	US$398k	US$7m

Compensatie versus markt: De totale vergoeding ($USD 1.22M ) Thomas } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).

Compensatie versus inkomsten: De vergoeding van Thomas is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Thomas Sandgaard (65 yo)

28.8yrs

Tenure

US$1,217,895

Compensatie

Mr. Thomas Sandgaard founded Zynex, Inc. in 1996 and has been its Chairman, Chief Executive Officer and President since 1996. Mr. Sandgaard served as the Chief Financial Officer and Chief Accounting Office...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Sandgaard	Founder	28.8yrs	US$1.22m	50.53% $ 125.6m
Daniel Moorhead	Chief Financial Officer	7.3yrs	US$883.15k	0.16% $ 396.5k
Anna Lucsok	Chief Operating Officer	3.8yrs	US$714.40k	0.053% $ 132.9k
Steve Fox	Vice President Of Sales	no data	geen gegevens	geen gegevens
Donald Gregg	President of Zynex Monitoring Solutions	1.8yrs	geen gegevens	geen gegevens
Neil Friery	President & COO of Zynex Monitoring Solutions	3.9yrs	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ZYXI wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Sandgaard	Founder	28.8yrs	US$1.22m	50.53% $ 125.6m
Barry Michaels	Independent Director	6.8yrs	US$159.70k	0.20% $ 488.7k
Michael Cress	Independent Director	6.8yrs	US$154.70k	0.20% $ 488.7k
Joshua Disbrow	Independent Director	6.6yrs	US$154.70k	0.23% $ 563.8k

6.8yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ZYXI wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

Zynex Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Chief Operating Officer recently sold US$199k worth of stock

Chief Financial Officer recently sold US$124k worth of stock

Zynex, Inc., Annual General Meeting, May 16, 2024

Chief Financial Officer recently sold US$170k worth of stock

Chief Financial Officer notifies of intention to sell stock

Insufficient new directors

Recent updates

Zynex, Inc. Obtains FDA Clearance for New Pain Management Device

Chief Operating Officer recently sold US$199k worth of stock

Investor sentiment deteriorates as stock falls 18%

Chief Financial Officer recently sold US$124k worth of stock

Consensus revenue estimates decrease by 11%

With Zynex, Inc. (NASDAQ:ZYXI) It Looks Like You'll Get What You Pay For

Price target decreased by 17% to US$17.50

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024

Zynex, Inc. to Report Q2, 2024 Results on Jul 25, 2024

Zynex, Inc.(NasdaqGS:ZYXI) dropped from Russell 2000 Growth-Defensive Index

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

Zynex, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Reaffirms for the Full Year 2024

Price target increased by 8.1% to US$19.88

First quarter 2024 earnings released: EPS: US$0 (vs US$0.043 in 1Q 2023)

Zynex, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Zynex, Inc., Annual General Meeting, May 16, 2024

Consensus EPS estimates fall by 11%

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. Provides Earnings Guidance First Quarter and Full Year 2024

Zynex, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Zynex, Inc. Introduces New Products

Zynex, Inc. Receives FDA Clearance for its Next Generation NMES Device

Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E

Zynex, Inc. Submits FDA Application for Its NMES Device

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $20 million worth of its shares.

Zynex, Inc. Provides Earnings Guidance for Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 24% to US$16.50

Investor sentiment deteriorates as stock falls 15%

Zynex, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Now 23% undervalued after recent price drop

Now 22% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Now 23% undervalued after recent price drop

Chief Financial Officer recently sold US$170k worth of stock

Chief Financial Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target increased by 11% to US$24.00

Zynex, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Zynex, Inc. Confirms Earnings Guidance for the Second Quarter of 2023 and Reiterates Earnings Guidance for the Full Year 2023

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Investor sentiment improves as stock rises 30%

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment deteriorates as stock falls 24%

Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Zynex, Inc. Reaffirms Earnings Guidance for the Fourth Quarter and Full Year 2022

Now 25% undervalued

Insufficient new directors

Chief Financial Officer recently sold US$407k worth of stock

Investor sentiment improved over the past week

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Third quarter 2022 earnings: EPS exceeds analyst expectations

Zynex, Inc. Provides Revenue Guidance for the Fourth Quarter 2022

Zynex, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Zynex, Inc. Re-Iterates Earnings Guidance for the Full Year 2022

Short Squeeze Candidate With Low PEG Ratio: Zynex

Zynex, Inc. Begins Enrollments in Large-Scale Blood Loss Detection Clinical Trial with its Second-Generation Monitoring System, CM-1600

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Zynex, Inc. Announces First Enrollments in Apheresis Donation Clinical Trial with Second Generation Fluid Monitoring System

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Zynex, Inc. Provides Revenue Guidance for the Third Quarter of 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations